AIM - AIM ImmunoTech extends prior research agreement to develop Ampligen as new inhalation therapy

AIM ImmunoTech (AIM) announces two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited, with the goal of developing Ampligen as a potential inhalation therapy for COVID-19 and other respiratory viral diseases.Initially, AIM entered into the agreement on April 1, 2020, to study the utilization of an innovative Smoore inhalation delivery device and Ampligen as a potential treatment approach for the SARS-CoV-2 pandemic."We are in the process of planning a Phase 1/2 inhalation clinical study on a parallel track with Smoore’s device development testing,” said AIM CEO Thomas K. Equels.AIM shares up 3.3% premarket trading at $2.18.

For further details see:

AIM ImmunoTech extends prior research agreement to develop Ampligen as new inhalation therapy